# Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

> **NCT03600701** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 51 (actual)

## Conditions studied

- Metastatic Lung Non-Small Cell Carcinoma
- Recurrent Lung Non-Small Cell Carcinoma
- Refractory Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8

## Interventions

- **DRUG:** Atezolizumab
- **PROCEDURE:** Biopsy Procedure
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Cobimetinib
- **PROCEDURE:** Computed Tomography
- **PROCEDURE:** Magnetic Resonance Imaging

## Key facts

- **NCT ID:** NCT03600701
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-11-29
- **Primary completion:** 2025-07-14
- **Final completion:** 2026-10-03
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2025-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03600701

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03600701, "Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT03600701. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*